New tobramycin/dexamethasone ophthalmic suspension launched
A new combination anti-inflammatory/anti-infective product (TobraDex ST, Alcon Inc.) has been launched in the United States.
Huenenberg, Switzerland-A new combination anti-inflammatory/anti-infective product (TobraDex ST, Alcon Inc.) has been launched in the United States.
The tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk for infection exists.
“This product was specifically designed to increase retention time on the eye, allowing the drug to calm inflammation and fight bacteria effectively,” said Stuart Raetzman, Alcon vice president, global marketing and area president for the United States. “Clinical studies indicated that 10 minutes after dosing, concentrations of [the product] remained on the ocular surface at levels high enough to kill 99.9% of ocular bacteria.”
The ophthalmic suspension is designed with properties to prevent settling, thereby ensuring the desired amount of dexamethasone delivery, according to the company. Also, it is formulated with low viscosity in the bottle in an effort to facilitate easier dispensing.
The most common side effects experienced with the use of the topical antibiotic and corticosteroid combination include eye pain, eyelid itching, eyelid swelling, eye redness, and possible increases in IOP leading to glaucoma.
